TrialBlood advances2023

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.

Li-Juan Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.